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We report some observations from our laboratory practice that might be important for the treatment of sickle cell disease (SCD).
We describe data from two cases indicating that iron depletion might have a beneﬁcial eﬀect diminishing the formation of HbS
in favor of HbF, possibly reducing the severity of the disease. We believe that it would be worthwhile to monitor the course of the
disease comparing cases with identical genotypes with and without iron depletion, and we advise to consider chelation therapy to
reduce iron overload in patients with SCD.
1.Introduction
Sickle cell disease (SCD), also called sickle cell anemia
(SCA), is one of the most common recessive conditions
in human kind. Selected by malaria, carriers are found at
high frequencies in African, Asian, and Mediterranean pop-
ulations and many aﬀected children are born from parents
who are both healthy carriers. The pathology is caused by
the polymerization of the anomalous hemoglobin tetramers
(HbS), that enclose a single amino acid substitution (Glu→
Val) at cd6 of the β-globin chains, induced by a GAG→GTG
mutation on the β-globin gene.
Polymerization takes place in the postcapillary veins and
can occur in less than one second, when the hemoglobin
tetramers,havingreleasedtheirloadoffouratomsofoxygen,
acquire their deoxy shape. The growing polymer ﬁbers
deformtheroundandelasticredcellsintosickleshapedrigid
erythrocytes that block the blood circulation. Sickle cells
trapped in the spleen may induce massive hemolysis, chronic
and acute infarctions in other organs, and in the skeleton
inducing excruciating pain (crises), with progressive organ
and tissues damage. The severe disease is leading to early
disability and premature death, treatment is only supportive,
cure might occur only in case of successful bone marrow
transplantation and primary prevention is oﬀered to couples
at risk in many countries [1, 2].
2.Pathology andGeneticBackground
The carriers of the trait (SCT), who are heterozygous for the
A→T mutation, have approximately 40–50% HbS (α2/βS2)
in all their red cells, and usually show no symptoms because
thenormalHbA(α2/βA2)codedbythenormalalleleinhibits
the polymerization process in the red cells. Nevertheless,
heterozygous may experience a milder transient pathology
during triggering conditions [3].
The patients (homozygous or compound heterozygous)
have inherited from both parents either the HbS gene or a
combination of the HbS heterozygosity with β-thalassemia,
HbC,HbE,HbD
Punjab,HbO
Arab,orotherlesscommontraits,
the combination of which allows polymerization of the Hb
tetramers in deoxy conditions.
The severity of SCD can be quite variable and may
express with very severe frequent crises and (fatal) compli-
cations or with only occasional crises and limited organ and
tissue damage.
3. ModulatingFactors: Genetic,
Externaland Therapy Related
The severity of the SCD phenotype depends on genetic,
external, and therapy-related factors. Among the genetic
modulating factors, the expression of fetal hemoglobin2 ISRN Hematology
(HbF) during post natal life is the most relevant. At birth,
under normal conditions, HbF (γ2/α2) is present in the
red cells at an average concentration of about 80% and it
normally disappears (below 1%) during the ﬁrst two years of
life. This is the reason why newborn with SCD are perfectly
healthy up to about 6 months of age, when the expression of
the fetal hemoglobin has disappeared. While in the normal
individuals HbF is replaced by the normal postnatal HbA,
in SCD the HbF expression will be replaced by the abnormal
HbS.InthehealthycarrierbothHbAandHbSwillbepresent
in an average ratio of 60:40.
In many cases of hereditary or acquired chronic anemia,
the HbF concentration may remain higher than normal
after birth. In SCD patients a moderate increase of 5–
10% HbF may already reduce the symptoms of SCD
considerably because HbF has a higher oxygen aﬃnity,
keeps some oxygen in the red cell in the postcapillary veins
and inhibits HbS polymerization. For this reason, hydroxy
urea (HU) treatment, a pharmacological enhancer of HbF
expression, is largely used in preventing the symptoms
of SCD [4] and also in β-thalassemia [5]. Not all these
patients will equally respond to HU treatment because the
natural and pharmacological expression of HbF in postnatal
life is genetically determined [6]. The main determinant
for a positive response is the presence of a particular
polymorphism (Xmn-I) on the beta gene haplotype [5].
This C→T transition on the promoter region of the Gγ
gene (the main contributor to HbF expression normally
silenced in adult life) is perhaps the most striking example of
pharmacogenomic speciﬁcity. Moreover, HU protects from
HbS polymerization because of the antiadherence eﬀect on
the red cells to the wall of the postcapillary veins [7].
A second important genetic factor modulating the sever-
ity of SCD is the coinheritance of α-thalassemia, another
commontraitinhuman,reducingtheexpressioninα-globin
chains, the non-β counterpart of both the fetal and postnatal
tetramers, including HbS.
Many carriers of SCT are also carriers of at least a
singleα+-thalassemiagene(−α/αα)orareoftenhomozygous
(−α/−α) for these traits, presenting with hypochromic
(MCH↓) and eventually microcytic (MCV↓) parameters and
a moderate anemia. In fact, the majority of the healthy
HbS carriers are identiﬁed “by accident”, after a patient
controlled by routine (HPLC) laboratory analysis because
of “microcytic anemia” not responding to iron therapy. The
modulating eﬀect of α-thalassemia has been long debated
[8].However,themanycasesfromourdiagnosticserviceand
the literature show a classic reduction of the HbS% in the
carrier, indicating that α-globin, when scarce, preferentially
bind to the normal βA rather than to the mutated βS globin
chains [9]. This alternative is of course not present in the
homozygous that has no βA chains to bind with α chains,
but other factors related to α-thalassemia might have a
modulating inﬂuence, perhaps the preferential binding of
α chains for the normal γ chains (if present) rather than
for βS, perhaps the reduction in MCH, diminishing the
stechiometric concentration of HbS in the red cells and
herewith the speed and the chance of HbS to polymerize,
perhaps the reduced size of the red cells (MCV↓) allowing
a faster rheology, diminishing the critical ﬂow-through time
and the chance of HbS polymerization in the post capillary
veins.
External and treatment-related modulating factor play
also a role in the course of the disease. Among the
external one, dehydration, temperature, oxygen tension, and
infections are the most important and will not be discussed
in this paper.
Besides the above mentioned response to HU therapy,
the treatment-related modulating factors are those related to
transfusion dependency and iron overload. The golden rule
in SCD treatment is to avoid blood transfusions as much
as possible using eventually exchange transfusion which
does not contribute to iron overload. Nevertheless, SCD
patients who are often hospitalized for severe hemolytic
crises are transfused and iron overloaded while some anemic
SCD patients might even get iron prescriptions. Therefore,
most SCD patients will have iron accumulation while iron
depletion is only rarely observed generally in patients who
(perhaps also thanks to that) have a mild phenotype. We
believe that iron depletion could be a modulating factor
which might contribute to ameliorate the phenotype of SCD
and that a large evidence based study could be taken into
consideration to validate our assumption illustrated by the
following cases.
4.Case1
We reported back in 2000 a case of HbS/β◦-Thalassemia with
a very mild pathology [10]. It concerned a mature woman
mother of two, diagnosed with SCD at age 24, presenting at
age 50 with the ﬁrst hemolytic crisis during an infectious
event (pneumonia). Patient showed a complete spleen
atrophy, her HbF was 7%, and she was also homozygous for
the most common α+-thalassemia form, the −α3.7 deletion
defect (−α/−α). Due to the combined β and α Thalassemia,
herHblevelwas9.8g/dLandherMCVandMCHlevelswere
typically reduced. Patient had never experienced an acute
crisis,hadneverreceivedabloodtransfusion,andherferritin
level was low normal.
Case 1 tells us that the SCD condition in this severe
HbS/β◦-Thalassemiagenotype wasprobablykept mild by(a)
7% HbF expression and (b) the presence of α-thalassemia
and of never treated iron depletion, not even during the two
iron requiring pregnancies, keeping this patients at low Hb,
MCV, MCH, and ferritin levels for all her life.
5.Case2
We have recently observed a 56 old female from Caribbean
origin presenting with 10.6g/dL Hb and a very pro-
nounced microcytic hypochromic anemia. The Hb pattern
was anomalous on HPLC, showing beside HbA a fraction
corresponding to HbS but representing only 10% of the
total. The patient had no HbF expression and an extreme
iron depletion (ZPP 700 μmol/mol in absence of led
intoxication) and was carrier of the same −α3.7 deletion as
in case 1 (−α/αα). The very low expression of the abnormalISRN Hematology 3
fraction indicated an α rather than a β-gene mutation,
but DNA sequence of the alpha genes was normal while
sequenceofthebetaglobingenesrevealedtheHbSmutation.
A percentage of 10% HbS was inexplicable even in the
presence of α-Thalassemia and after iron suppletion, the
HbS concentration raised rapidly to 35%, the level expected
in the HbS heterozygous in the presence of α+-thalassemia
heterozygosity.
TheanomalousHbexpressioninthisanemicHbScarrier
tells us a few interesting things, namely that (a) the 10% HbS
expression was not caused by the well-known preferential
aﬃnity for the formation of α/βA rather than α/βS dimers
in the presence of the (−α/αα) genotype, and that (b)
the HbS expression increased to the expected level of 35%
after iron suppletion. This means that under conditions of
iron depletion, the heme tends to be imbedded into the
normal βArather than into the abnormal βS chains. These
could also mean that in SCD and in condition of iron
depletion, the expression of HbS could be inhibited in favor
of the normal HbF. This cannot be demonstrated in this
patientswho,beingheterozygousandinabsenceoftheXmnI
polymorphism, had no elevated HbF expression before or
after iron therapy.
6. Discussion
The point to be further investigated is: could iron depletion,
which induces low MCV and MCH just like α-thalassemia,
have a positive modulating eﬀect on the severity of SCD
also because of a reduction of HbS expression in favor of an
increased HbF?
The iron housekeeping in our body is characterized
by an eﬃcient recycling and under normal conditions the
main iron storage consists of the iron atoms built into the
hemoglobin molecules. Each Hb tetramers contains 4 atoms
harbored in the center of the 4 prosthetic groups and under
normal conditions “heme iron” is fully recycled, while intake
versus loss through the guts (±2mg a day) is in slightly
positive balance.
The most signiﬁcant nondisease-related changes in iron
stores takes place during pregnancy (loss of 1000mg) and
during blood transfusion (gain of 200mg fully absorbed
from one bag of packed red cells).
A signiﬁcant increase in iron absorption is known
to occur in thalassemia carriers. Therefore, treating the
moderate anemia of these patients with iron therapy without
checkingtheferritinlevelsisuselessandcouldbedeleterious.
The beta thalassemia major patient is transfusion depen-
dent and secondary toxic overload is one of the major
complications leading to premature death from cardiac
disease. However, recent developments combining diﬀerent
chelating agents have led to a considerable health gain and
life expectations [11].
In SCD treatment blood transfusion should be avoided
as much as possible to limit iron accumulation. When
blood transfusions are inevitable, the PCV value should
not become too elevated, not to reduce the rheology in
the postcapillary veins. Exchange transfusions without iron
accumulation should be preferred when possible and be
applied as a prophylactic measure to reduce crises frequency
inseverecases.Unfortunately,beingtheferritinthresholdfor
chelation therapy usually 1000μg/L, SCD patients below this
level are usually not chelated and live in a chronic state of
iron overload.
These authors do not need to underline the problems
r e l a t e dt oi r o no v e r l o a db u tw o u l dl i k et od r a wa t t e n t i o nt o
the cases illustrated above, which indicate that iron depletion
couldbeapossiblemodulatingfactorinreducingtheseverity
of the pathology of SCD and that the usually accepted iron
overload (up to 1000μg/L) could be an aggravating factor
that may favor HbS polymerization.
Iron depletion is not often observed in SCD. Never-
theless, based on the facts presented in our two cases,
we have reasons to believe that keeping a SCD patient,
especially if treated with hydroxyurea, at a low ferritin
level by avoiding transfusions and/or by applying chelation
therapy, might reduce the pathology of the disease by (a)
favoring the formation of HbF rather than HbS tetramers,
(b) by improving the rheology (low MCV), and reducing the
molecular contacts in the red cell (low MCH) and herewith
the chance of HbS polymerization and infarctions.
We suggest that it might be worthwhile to monitor the
clinical course of the disease in patients with and without
iron depletion, with or without hydroxyurea treatment, and
with the same SCD genotype.
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